Hypertension functional nutrition repairing product

By combining thirst buckwheat peptide, mung bean powder and γ-aminobutyric acid in food and medicine homologous cereals, the problem of limited effects of existing food-borne blood pressure lowering products in the human body is solved, and the patient's blood pressure has been significantly improved. It has significant therapeutic effects, especially for patients with long-term illness.

CN118985922APending Publication Date: 2024-11-22JIANGNAN UNIV
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202411061737.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-05
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The existing foodborne blood pressure-lowering nutritional products have limited effect on lowering blood pressure in the human body, especially for patients with chronic illness, which is difficult to achieve significant blood pressure lowering alone.

Method used

Using active buckwheat peptide and mung bean powder in food and medicine homologous cereals, combined with the physiological endogenous functional ingredient γ-aminobutyric acid, a blood pressure regulation system is repaired through multiple latitudes, and a blood pressure lowering composition or compound preparation is developed to optimize Formulation and preparation process to improve blood pressure lowering effect.

Benefits of technology

A good blood pressure lowering effect on patients with hypertension in different disease stages has been achieved, with a maximum systolic blood pressure drop of 40mmHg and a maximum systolic blood pressure drop of 25mmHg. The effective efficiency for patients under 5 years is ≧83%, and the effective efficiency for patients over 5 years is ≧75%, and Show good results when used alone or in combination with antihypertensive drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118985922A_ABST
    Figure CN118985922A_ABST
Patent Text Reader

Abstract

The invention discloses a functional nutrition repairing product for hypertension, and belongs to the technical field of medicines or healthy foods. The tartary buckwheat protein peptide and the mung bean powder which are high in activity in food and medicine homologous cereals are selected and matched with a physiological functional component gamma-aminobutyric acid to form a blood pressure lowering product, a damaged blood pressure regulation system is tried to be nursed from multiple latitudes, and nutrition repair and treatment are organically combined. Through multiple times of formula optimization and multiple rounds of crowd tests, the product has a relatively good blood pressure lowering effect on long-term (more than 5 years) hypertension patients.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of medicine or health food, and specifically relates to a functional nutritional repair product for hypertension. Background Art

[0002] With the rapid aging of my country's population, the incidence of chronic diseases such as hypertension is increasing rapidly. There are about 250 million people with hypertension in my country, and the trend of younger people is intensifying. Cardiovascular disease is the main cause of death in my country, and hypertension is the primary risk factor for cardiovascular disease. Existing drug treatments can only control but not cure hypertension, and have large side effects. As the duration of the disease increases, the control effect of drugs will continue to decline, causing patients to take more and more medicines and continuous complications, often leaving doctors and patients helpless.

[0003] Reasonable nutrition is the basis for improving patients' physique, inhibiting the development of diseases, and promoting the body's recovery. Although the pathogenesis of hypertension is complex, most of them are lifestyle diseases. Functional nutritional intervention for hypertension has the advantages of improving physical functions and few side effects. It is increasingly valued by all parties and has good development prospects. Among them, small-molecule food-derived oligopeptides are safe and reliable to eat, and are significantly better than complete proteins, amino acids and polypeptides with larger molecular weights in terms of absorption and utilization by the body. They can be used in health foods, special medical foods, special diets, and ordinary foods. At the same time, food-derived oligopeptides also have multiple physiological functions such as enhancing immunity, anti-oxidation, and assisting in regulating blood sugar, blood lipids, and blood pressure, and are particularly suitable for the development of special dietary foods.

[0004] At present, in order to avoid the side effects of hypertension drug treatment and achieve blood pressure reduction at the same time, food-derived blood pressure-lowering products are receiving more and more attention. For example: the existing literature (Development of food-derived oligopeptides and special dietary foods. Pan Xingchang et al., Nutrition and Food-Healthy China Senior Forum. 2008.) reported that whey protein peptides, egg albumin peptides, soybean protein peptides, corn peptides and other food-derived oligopeptides have different degrees of inhibition of angiotensin enzyme (ACE) activity through in vitro blood pressure reduction experiments; the existing literature (Enzymatic hydrolysis of buckwheat bran protein to produce blood pressure-lowering peptides. Lin Rufa et al., Food Science [J]. 2004.) reported that the peptides formed after enzymatic hydrolysis of buckwheat bran protein have blood pressure-lowering effects; the existing literature (Extraction of buckwheat functional peptides and study of their blood pressure-lowering activity. Chen Hua, Changchun University of Technology [D]. 2015.) reported that buckwheat flour was used as raw material and alkaline protease was used to enzymatically hydrolyze buckwheat blood pressure-lowering peptides; and the patent document CN202211364418 reported a highly active buckwheat albumin blood pressure-lowering peptide. However, most of the food-borne blood pressure-lowering functional products reported above have only been proved to have certain angiotensinase inhibitory activity and may have certain blood pressure-lowering effects through in vitro experiments or animal experimental models. However, on the one hand, in vitro experiments are separated from the overall environment and cannot simulate the real situation of the human body. It is still a long way to extrapolate the results of in vitro experiments to the biology of complete organisms, which is challenging. On the other hand, the animal model experiments reported so far are all single modeling methods, such as AngⅡ-induced hypertension animal model, deoxycorticosterone acetate-induced hypertension animal model, or genetic engineering hypertension model, etc., and the etiology of hypertension patients is usually very complicated. It is difficult to prove that the model experiments under a certain modeling method have therapeutic effects on different groups of hypertension patients with complex etiologies. In addition, there are great differences between animal models and human biological systems, and it is difficult to show the same symptoms as humans. It is impossible to simulate accurately, and many errors will occur in the research process, which makes the human treatment effect inaccurate. At present, the actual human blood pressure-lowering therapeutic effects of these food-borne products reported so far are very limited, especially for patients with hypertension with a long disease period. Summary of the invention

[0005] Technical issues:

[0006] Most of the existing food-derived blood pressure lowering functional nutritional products have the problem of not having an obvious blood pressure lowering effect. In practical use, they are mostly preventive or auxiliary effects, especially for patients with hypertension with a long illness period (≧5 years). The blood pressure lowering effect is poor, and it is difficult to stand alone. In order to solve the above problems, the present invention selects bitter buckwheat peptides and mung bean powder with strong activity in food and medicine homologous cereals, and simultaneously adds physiological endogenous functional ingredients γ-aminobutyric acid to formulate a blood pressure lowering product, trying to repair the damaged blood pressure regulation system from multiple dimensions, and organically combining functional nutritional repair with treatment. After multiple formulation optimizations and multiple rounds of population testing, the product has achieved a good blood pressure lowering effect on hypertensive patients at different stages of illness.

[0007] Technical solution:

[0008] The invention provides a blood pressure lowering composition or compound preparation, comprising the following components: tartary buckwheat peptide, mung bean powder and gamma-aminobutyric acid.

[0009] The invention provides a blood pressure lowering composition or composite preparation, which is prepared from the following raw materials in the following weight proportions as effective components: 3-8 parts of tartary buckwheat peptide, 1-6 parts of mung bean powder, and 0.01-0.25 parts of gamma-aminobutyric acid.

[0010] In one embodiment of the present invention, the composition is further composed of the following parts by weight: 4-8 parts of tartary buckwheat peptide, 1-5 parts of mung bean powder, and 0.01-0.25 parts of γ-aminobutyric acid.

[0011] In one embodiment of the present invention, the mass ratio of mung bean powder to tartary buckwheat peptide is 1:(0.5-4), preferably 1:(0.8-4), and more preferably 1:(1-4).

[0012] In one embodiment of the present invention, the mass fraction of γ-aminobutyric acid relative to the total amount of the blood pressure lowering composition or preparation is 0.1%-2.5%.

[0013] The present invention also provides the use of a combined system of tartary buckwheat peptide, mung bean powder and gamma-aminobutyric acid in the preparation of a blood pressure lowering compound preparation.

[0014] In one embodiment of the present invention, in the above application, the tartary buckwheat peptide has a synergistic effect of lowering blood pressure with mung bean powder and γ-aminobutyric acid.

[0015] In one embodiment of the present invention, the molecular weight (Mw) of the above-mentioned buckwheat peptide is ≦1400Da, and the proportion is ≧95%.

[0016] In one embodiment of the present invention, the above-mentioned buckwheat peptide is prepared by the following method: the buckwheat is crushed and defatted, and then the protein is precipitated by alkali dissolution and acid precipitation, the protein precipitate is collected, and then centrifuged, dried, and crushed to obtain buckwheat protein powder; the buckwheat protein powder is then enzymatically hydrolyzed to obtain an enzymatic hydrolyzate, and the enzymatic hydrolyzate is concentrated and dried to obtain the buckwheat peptide.

[0017] In one embodiment of the present invention, the mung bean powder is prepared by the following method:

[0018] The mung bean raw material is washed and subjected to high temperature ripening treatment at 180-210° C. for 1-15 minutes, and then crushed and screened to obtain mung bean powder.

[0019] In one embodiment of the present invention, the compound preparation is a food preparation or a pharmaceutical preparation.

[0020] In one embodiment of the present invention, the dosage form of the composite preparation is a solid preparation, a liquid preparation, or a semisolid preparation.

[0021] In one embodiment of the present invention, the solid preparation may specifically be a beverage powder.

[0022] In one embodiment of the present invention, the preparation may further include other components.

[0023] In one embodiment of the present invention, the other components are commonly used functional additives, such as solubilizers, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, and aromatics.

[0024] In one embodiment of the present invention, the other components are functional components or nutritional components, such as astragalus, purslane, licorice, wolfberry, ginseng, kudzu root, chicory, konjac, mulberry, yam, lotus seed, hawthorn, ginkgo, coix seed, germinated brown rice, resistant dextrin, rice protein peptide, soy protein peptide, mung bean protein peptide, oat protein peptide, highland barley protein peptide, soy protein peptide, quinoa protein peptide, pea protein peptide, peanut protein peptide, corn protein peptide, walnut protein peptide, whey protein peptide, and ovalbumin peptide.

[0025] The present invention also provides the use of a combined system of tartary buckwheat peptide, mung bean powder and γ-aminobutyric acid in the preparation of a blood pressure lowering compound preparation. The combined system of tartary buckwheat peptide, mung bean powder and γ-aminobutyric acid has a synergistic blood pressure lowering effect, especially for hypertensive patients with a long history of the disease.

[0026] The present invention also provides the use of the above composition or preparation in the preparation of blood pressure lowering drugs.

[0027] The present invention also provides the use of the above composition or preparation in preparing health-care food, special medical food, special diet and ordinary food for maintaining healthy blood pressure level.

[0028] Beneficial effects:

[0029] On the one hand, the present invention selects bitter buckwheat protein peptides and mung bean powder, which are highly active among the grains with the same origin as food and medicine, and simultaneously uses the physiological functional component γ-aminobutyric acid to formulate a blood pressure lowering product, attempting to regulate the damaged blood pressure control system from multiple dimensions, and organically combining nutritional repair with treatment. The product of the present invention has a strong blood pressure lowering effect, and can significantly reduce the blood pressure of hypertensive patients with different conditions and courses of disease, with a maximum reduction of 40 mmHg in systolic blood pressure and a maximum reduction of 25 mmHg in diastolic blood pressure, and the effective rate for patients with a history of hypertension for less than 5 years is ≥ 83%, and the effective rate for patients with a history of hypertension for more than 5 years is ≥ 75%.

[0030] On the other hand, the product of the present invention further shows good blood pressure lowering effect in the prevention and treatment of hypertension whether used alone or together with antihypertensive drugs. It can be used to treat hypertension alone or in combination with drugs. It has a significant blood pressure lowering effect, especially for hypertensive patients who have failed drug treatment, with an effective rate of ≥72%. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] Figure 1 This is a digital photo of the beverage powder product obtained in Example 1.

[0032] Figure 2 This is the molecular weight distribution diagram of the buckwheat peptide used in the present invention.

[0033] Figure 3 This is a diagram showing the inhibitory effect of the tartary buckwheat peptide used in the present invention on ACE.

[0034] Figure 4 This is a comparison chart of blood pressure changes within 30 days after a patient with a 2-year history of hypertension (not taking medication) took the composite preparation obtained in Example 1. (Days 1-5 refers to the average value of this stage, and the rest are analogous)

[0035] Figure 5 This is a comparison chart of blood pressure changes within 30 days after a patient with a 3-year history of hypertension (not taking medication) took the composite preparation obtained in Example 1. (Days 1-5 refers to the average value of this stage, and the rest are analogous)

[0036] Figure 6 This is a comparison chart of blood pressure changes within 30 days after a patient with 8 years of hypertension history (not taking medication) took the composite preparation obtained in Example 1. (Days 1-5 refers to the average value of this stage, and the rest are analogous)

[0037] Figure 7This is a comparison chart of blood pressure changes within 25 days after a patient with a 10-year history of hypertension (not taking medication) took the composite preparation obtained in Example 1. (Days 1-5 refers to the average value of this stage, and the rest are analogous)

[0038] Figure 8 This is a comparison chart of blood pressure changes within 25 days after a patient with a 5-year history of hypertension (100 mg sacubitril valsartan sodium tablets, 1 tablet per day, but no significant antihypertensive effect) took the composite preparation obtained in Example 1. (Days 1 to 5 refer to the average value of this stage, and the rest are analogous)

[0039] Fig. 9 This is a comparison chart of blood pressure changes within 45 days after a patient with a 23-year history of hypertension (atropol, amlodipine tablets, and valsartan tablets each day, but with no significant antihypertensive effect) took the composite preparation obtained in Example 1. (Days 1-5 refers to the average value of this stage, and the rest are analogous)

[0040] Fig.10 Schematic diagram of the method for recording blood pressure data of volunteers. DETAILED DESCRIPTION

[0041] The tartary buckwheat peptides involved in the present invention are obtained by enzymatic hydrolysis of tartary buckwheat protein, and the molecular weight thereof is mainly no more than 1400Da. The present invention is based on one or more enzymatic hydrolysis processes of proteases such as pepsin, trypsin, neutral protease, alkaline protease, papain, etc. to obtain tartary buckwheat peptides with a molecular weight mainly no more than 1400Da, and these tartary buckwheat peptides can be used for the preparation of the hypertension functional nutritional repair product of the present invention.

[0042] One of the enzymatic hydrolysis processes of tartary buckwheat peptide involved in the following embodiments includes:

[0043] Using a buffer solution to prepare a tartary buckwheat protein dispersion and adjusting the pH to 1.5-2.5;

[0044] Then pepsin was added for 2 h of hydrolysis, and the pH was adjusted to 6.5-7.5 after the hydrolysis was completed;

[0045] Then trypsin and neutral protease are added to continue hydrolysis to obtain an enzymatic solution;

[0046] The enzymatic hydrolysate is then processed through filtering, concentration, drying, packaging and other production processes to obtain buckwheat peptide powder.

[0047] A tartary buckwheat peptide involved in the following embodiments can be prepared by the following preparation process:

[0048] (1) Protein extraction

[0049] Fresh buckwheat flour was ground, passed through a 60-mesh sieve, and defatted by adding petroleum ether and air-dried to obtain defatted buckwheat flour. The flour was mixed with water at a material-water ratio of 1:12 (m / v), and the pH was adjusted to 10.00 by 1 mol / L NaOH solution. The crude protein was extracted by stirring for 50 min during the heating to 55 °C. After the alkali dissolution was completed, the supernatant was obtained by centrifugation at 5000 r / min for 15 min. The pH of the supernatant was adjusted to 3.00 by 1 mol / L HCl solution, which was close to the isoelectric point of buckwheat protein. The supernatant was precipitated for 1 h, centrifuged at 5000 r / min for 15 min, and the precipitate was taken out for drying, crushing, packaging and other processing to obtain the finished buckwheat protein powder.

[0050] (2) Protein enzymatic hydrolysis

[0051] A 6% (m / v) tartary buckwheat protein dispersion was prepared with phosphate buffer (pH 7), and then the pH was adjusted to 2.00 with 1 mol / L HCl, and pepsin with a protein content of 6% was added, and hydrolyzed at 37°C for 2 hours. Then, the pH was adjusted to 7.00 with 1 mol / L NaOH, and 5% trypsin and 4% neutral protease with a protein content were added, and the hydrolysis was continued at 37°C for 1.5 hours to obtain an enzymatic hydrolyzate, which was then filtered, concentrated, dried, packaged, and processed to obtain tartary buckwheat peptide powder.

[0052] The molecular weight (Mw) of the obtained buckwheat peptide was determined to be ≦1331Da, accounting for ≧96%; the specific distribution was Mw=14491 accounting for 0.07%, Mw=5953 accounting for 0.11%, Mw=3711 accounting for 1.02%, Mw=2417 accounting for 1.93%, Mw=1331 accounting for 8.13%, Mw=667 accounting for 21.46%, Mw=291 accounting for 56%, Mw=106 accounting for 11.28%. The results are as follows Figure 2 (Peak curve diagram).

[0053] The ACE inhibitory activity of the obtained buckwheat peptide was determined. Figure 3 As shown, IC 50 It is 0.85mg / mL.

[0054] The preparation of mung bean powder involved in the present invention is as follows: mung beans are ground into powder after being cooked. The specific preparation process includes the following steps:

[0055] The mung bean raw material was washed and ripened at 200°C for 2 minutes, and then crushed through 80 mesh to obtain mung bean powder.

[0056] Example 1

[0057] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following: (total amount 10g)

[0058] composition Dosage(g) Buckwheat peptide 6.95 Mung Bean Powder 2.90 GABA 0.15

[0059] The specific preparation process is as follows: mung bean powder, tartary buckwheat peptide and gamma-aminobutyric acid are mixed evenly according to the above amounts, and the mixture is packaged to prepare a beverage powder product.

[0060] Example 2

[0061] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0062] composition Dosage(g) Buckwheat peptide 4.93 Mung Bean Powder 4.92 GABA 0.15

[0063] The specific preparation process is the same as that in Example 1.

[0064] Example 3

[0065] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0066] composition Dosage(g) Buckwheat peptide 7.50 Mung Bean Powder 2.35 GABA 0.15

[0067] The specific preparation process is the same as that in Example 1.

[0068] Example 4

[0069] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0070] composition Dosage(g) Buckwheat peptide 7.71 Mung Bean Powder 2.14 GABA 0.15

[0071] The specific preparation process is the same as that in Example 1.

[0072] Example 5

[0073] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0074] composition Dosage(g) Buckwheat peptide 7.88 Mung Bean Powder 1.97 GABA 0.15

[0075] The specific preparation process is the same as that in Example 1.

[0076] Example 6

[0077] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0078]

[0079]

[0080] The specific preparation process is the same as that in Example 1.

[0081] Example 7

[0082] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0083] composition Dosage(g) Buckwheat peptide 6.92 Mung Bean Powder 2.88 GABA 0.20

[0084] The specific preparation process is the same as that in Example 1.

[0085] Example 8

[0086] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0087] composition Dosage(g) Buckwheat peptide 6.88 Mung Bean Powder 2.87 GABA 0.25

[0088] The specific preparation process is the same as that in Example 1.

[0089] Comparative Example 1

[0090] Simple and equal amounts of buckwheat peptides.

[0091] composition Dosage(g) Buckwheat peptide 6.95

[0092] Comparative Example 2

[0093] Simply equal amount of mung bean powder.

[0094] composition Dosage(g) Mung Bean Powder 2.90

[0095] Comparative Example 3

[0096] Equal amounts of gamma-aminobutyric acid.

[0097] composition Dosage(g) GABA 0.15

[0098] Comparative Example 4

[0099] Referring to Example 1, under the premise of keeping the total amount unchanged, γ-aminobutyric acid is omitted:

[0100] composition Dosage(g) Buckwheat peptide 7.10 Mung Bean Powder 2.90

[0101] The specific preparation process is the same as that in Example 1.

[0102] Comparative Example 5

[0103] Referring to Example 1, mung bean powder is omitted under the premise of keeping the total amount unchanged:

[0104] composition Dosage(g) Buckwheat peptide 9.85 GABA 0.15

[0105] The specific preparation process is the same as that in Example 1.

[0106] Comparative Example 6

[0107] Referring to Example 1, omitting the tartary buckwheat peptide while keeping the total amount unchanged:

[0108] composition Dosage(g) Mung Bean Powder 9.85 GABA 0.15

[0109] The specific preparation process is the same as that in Example 1.

[0110] Comparative Example 7

[0111] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0112] composition Dosage(g) Buckwheat peptide 2.32 Mung Bean Powder 7.53 GABA 0.15

[0113] The specific preparation process is the same as that in Example 1.

[0114] Comparative Example 8

[0115] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0116]

[0117]

[0118] The specific preparation process is the same as that in Example 1.

[0119] Comparative Example 9

[0120] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0121] composition Dosage(g) Buckwheat peptide 8.69 Mung Bean Powder 1.16 GABA 0.15

[0122] The specific preparation process is the same as that in Example 1.

[0123] Comparative Example 10

[0124] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0125] composition Dosage(g) Buckwheat peptide 7.050 Mung Bean Powder 2.945 GABA 0.005

[0126] The specific preparation process is the same as that in Example 1.

[0127] Comparative Example 11

[0128] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0129] composition Dosage(g) Buckwheat albumin antihypertensive peptide 6.95 Mung Bean Powder 2.90 GABA 0.15

[0130] The specific preparation process is the same as that in Example 1.

[0131] Among them, the tartary buckwheat albumin antihypertensive peptide was prepared with reference to document CN116479077A.

[0132] Comparative Example 12

[0133] Referring to Example 1, an equal amount of tartary buckwheat peptide was replaced with corn oligopeptide, and the rest remained unchanged.

[0134] Comparative Example 13

[0135] Referring to Example 1, an equal amount of tartary buckwheat peptide was replaced with soybean protein peptide, and the rest remained unchanged.

[0136] Comparative Example 14

[0137] Referring to Example 1, an equal amount of tartary buckwheat peptide was replaced with ovalbumin peptide, and the rest remained unchanged.

[0138] Comparative Example 15

[0139] Referring to Example 1, an equal amount of tartary buckwheat peptide was replaced with whey protein peptide, and the rest remained unchanged.

[0140] Example 9

[0141] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0142] composition Dosage(g) Buckwheat peptide 6.95 Mung Bean Powder 2.90 GABA 0.15 Ginseng powder 0.02 Licorice powder 0.01 purslane 0.005 Quinoa protein peptide 0.002 Oat protein peptide 0.002

[0143] The specific preparation process is as follows: the components are mixed evenly according to the above amounts, and the beverage powder product is prepared after packaging.

[0144] Example 10

[0145] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0146] composition Dosage(g) Buckwheat peptide 6.95 Mung Bean Powder 2.90 GABA 0.15 Wolfberry powder 0.02 Pueraria root powder 0.01 Resistant dextrin 0.005 Whey Protein Peptides 0.002 Ovalbumin peptide 0.002

[0147] The specific preparation process is as follows: the components are mixed evenly according to the above amounts, and the beverage powder product is prepared after packaging.

[0148] Embodiment 11

[0149] This embodiment provides a hypertension function nutritional repair granule product, which is composed of the following:

[0150]

[0151]

[0152] The specific preparation process is as follows: the components are mixed evenly according to the above amounts, and the beverage powder product is prepared after packaging.

[0153] Test Case

[0154] The blood pressure lowering effect of the hypertension function nutritional repair granules obtained in the above embodiments and control examples was tested:

[0155] Description of the test process: Recruit patients with mild to moderate hypertension as volunteers, the inclusion criteria are 140≦systolic blood pressure≦179mmHg and / or 90≦diastolic blood pressure≦109mmHg, the test period is 60 days, and patients measure and record their blood pressure twice a day, once in the morning and once in the evening. The number of volunteers in each embodiment or control group is 30-90 people. The product is taken twice a day with warm water, one bag of each embodiment or control beverage powder product at a time (with an interval of 8 hours). Volunteers can be divided into two patient groups: patients with a history of hypertension for less than 5 years, and patients with a history of hypertension for more than 5 years; further, it also includes a group of hypertensive patients who have failed treatment with different antihypertensive drugs (such as dihydropyridines, sartans). According to Fig.10 The relevant blood pressure data of the volunteers were obtained by the recording method shown.

[0156] Calculation of blood pressure lowering effectiveness = number of volunteers participating in the test whose blood pressure returned to the effectiveness reference index / total number of volunteers participating in the test.

[0157] The reference indicators for effectiveness are: a decrease in systolic blood pressure ≥ 20 mmHg and / or a decrease in diastolic blood pressure ≥ 10 mmHg.

[0158] The test results are shown in Table 1.

[0159] Table 1

[0160]

[0161]

[0162] Function and effect:

[0163] As can be seen from the above table, the products of each embodiment of the present invention can significantly lower the blood pressure of hypertensive patients with different conditions and courses of disease, with the maximum reduction of systolic blood pressure being 40 mmHg and the maximum reduction of diastolic blood pressure being 25 mmHg. The effective rate within 5 years is over 83%, and can reach as high as 95%. The effective rate over 5 years is over 75%, and can reach as high as 87% (reference indicators for effective rate: reduction of systolic blood pressure ≧20 mmHg and / or diastolic blood pressure ≧10 mmHg).

[0164] From the data in Table 1, it can be seen that although the single bitter buckwheat peptide (reference example 1) has a certain blood pressure lowering effect on hypertensive patients under 5 years, it has a poor effect on hypertensive patients over 5 years and basically has no stable therapeutic effect; the single mung bean powder (reference example 2) or the single γ-aminobutyric acid (reference example 3) has an even worse effect, and has no significant and effective therapeutic effect on hypertensive patients under 5 years, and has basically no effect on hypertensive patients over 5 years. However, when the bitter buckwheat peptide is combined with mung bean powder and γ-aminobutyric acid, it has a good and stable blood pressure lowering effect on hypertensive patients under 5 years and over 5 years. It can be seen that the bitter buckwheat peptide has a significant synergistic effect with mung bean powder and γ-aminobutyric acid in lowering blood pressure, especially the synergistic effect on hypertensive patients over 5 years is more significant.

[0165] For patients with hypertension who have failed to respond to different antihypertensive drugs (e.g., dihydropyridine, sartan) Figure 8-9 As shown, taking the product of Example 1 of the present invention can also have a significant blood pressure lowering effect, and the effective rate is 72%; and the formula products of other Examples 2-8 can also achieve good blood pressure lowering effects.

[0166] In addition, on the basis of the formula of embodiments 1-8 of the present invention, some functional components or nutritional components can be further added: astragalus, purslane, liquorice, wolfberry, ginseng, kudzu root, chicory, konjac, mulberry, yam, lotus seed, hawthorn, ginkgo, coix seed, germinated brown rice, resistant dextrin, rice protein peptide, soybean protein peptide, mung bean protein peptide, oat protein peptide, highland barley protein peptide, soybean protein peptide, quinoa protein peptide, pea protein peptide, peanut protein peptide, corn protein peptide, walnut protein peptide, whey protein peptide, ovalbumin peptide. The resulting composite formula (such as embodiments 9-11) all has a significant blood pressure lowering effect, and has a very good blood pressure lowering effect on hypertensive patients of more than 5 years and hypertensive patient groups who have failed to treat with different antihypertensive drugs (such as dihydropyridines and sartans).

[0167] The embodiments provided above are not intended to limit the scope of the present invention, and the steps described are not intended to limit the execution order thereof. Those skilled in the art may make obvious improvements to the present invention in combination with existing common knowledge, which also fall within the scope of protection defined by the claims of the present invention.

Claims

1. A blood pressure lowering composition or preparation product, characterized in that: Contains the following ingredients: buckwheat peptide, mung bean powder, and γ-aminobutyric acid.

2. A blood pressure lowering composition or preparation product, characterized in that: The invention is prepared from the following raw materials in the following weight proportions as effective components: 3-8 parts of tartary buckwheat peptide, 1-6 parts of mung bean powder and 0.01-0.25 parts of gamma-aminobutyric acid.

3. The blood pressure lowering composition or preparation product according to claim 1 or 2, characterized in that: The mass ratio of mung bean powder to tartary buckwheat peptide is 1:(0.5-4); the mass fraction of gamma-aminobutyric acid relative to the total amount of the blood pressure lowering composition or preparation is 0.1%-2.5%.

4. The blood pressure lowering composition or preparation product according to claim 1 or 2, characterized in that: The dosage form of the preparation is a solid preparation, a liquid preparation, or a semisolid preparation.

5. The blood pressure lowering composition or preparation product according to claim 4, characterized in that: The solid preparation may specifically be a beverage powder.

6. The blood pressure lowering composition or preparation product according to claim 1 or 2, characterized in that: The preparation further comprises other components, which are commonly used functional adjuvants selected from any one or more combinations of the following: cosolvents, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, stabilizers, glidants, flavoring agents, preservatives, suspending agents, and aromatics.

7. The blood pressure lowering composition or preparation product according to claim 1 or 2, characterized in that: The preparation also contains other components, which are functional components or nutritional components and are selected from any one or more of the following combinations: astragalus, purslane, licorice, wolfberry, ginseng, kudzu root, chicory, konjac, mulberry, yam, lotus seed, hawthorn, ginkgo, coix seed, germinated brown rice, resistant dextrin, rice protein peptide, soybean protein peptide, mung bean protein peptide, oat protein peptide, highland barley protein peptide, soybean protein peptide, quinoa protein peptide, pea protein peptide, peanut protein peptide, corn protein peptide, walnut protein peptide, whey protein peptide, and egg albumin peptide.

8. Application of a combined system of tartary buckwheat peptide, mung bean powder and γ-aminobutyric acid in the preparation of a blood pressure lowering compound preparation, characterized in that: Buckwheat peptide, mung bean powder and γ-aminobutyric acid have a synergistic effect in lowering blood pressure, especially in patients with hypertension with a long history of illness.

9. Use of the blood pressure lowering composition or preparation product according to any one of claims 1 to 7 in the preparation of blood pressure lowering drugs.

10. Use of the blood pressure lowering composition or preparation product according to any one of claims 1 to 7 in the preparation of health food, special medical food, special diet, or ordinary food for maintaining a healthy blood pressure level.

Citation Information

Patent Citations

  • A mung bean protein peptide having ACE inhibitory activity and a preparation method and applications thereof

    CN103290086A

  • Health-maintenance mung-bean fried leavened flour and production process thereof

    CN106690064A

  • Clam peptide compound for protecting cardiovascular system and kidney and application of clam peptide compound

    CN114271502A

  • Preparation method of high-activity tartary buckwheat albumin antihypertensive peptide

    CN116479077A

  • Preparation and screening method of tartary buckwheat albumin antihypertensive peptide with renin inhibitory activity

    CN117247425A